Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Nar
Go back to Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Nar| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 253.96 +3.55 (1.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $250.41 | 52 Week High | $160.00 | |||
| Open | $248.38 | 52 Week Low | $95.80 | |||
| Day High | $254.58 | P/E | 47.20 | |||
| Day Low | $248.38 | EPS | $5.38 | |||
| Volume | 315,709 | |||||
